InflaRx – a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system – has announced positive topline data from its phase 2a basket study evaluating INF904 as a potential treatment for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).
HS and CSU are chronic inflammatory skin conditions characterised by rashes, abscesses, inflammation and scarring.
INF904 is an orally administered, small molecule inhibitor of the C5a receptor (C5aR1) that has demonstrated anti-inflammatory activity across several preclinical disease models. According to InflaRx, pharmacokinetic and pharmacodynamic data support the candidate’s best-in-class potential for blocking C5a-induced neutrophil activation.
The safety and efficacy of INF904 are being assessed in two multicentre, open-label phase 2a studies, each exploring multiple dosing regimens over a four-week treatment period.
Topline results from both studies indicated treatment efficacy across patient cohorts, with InflaRx reporting improvements in clinical scores for 29 out of 31 HS patients and 30 out of 31 CSU patients.
Professor Niels Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “The success of our p2a trial with INF904 in HS and CSU is a crucial milestone in demonstrating the compound’s strong safety profile and clinical activity as a potent anti-inflammatory agent.
“The data represent a pivotal moment for the company, underscoring the therapeutic promise of INF904 as a pipeline-in-a-product.
“As we move toward initiating phase 2b in HS and broadening the INF904 clinical programme in CSU and beyond, we look forward to further validating INF904’s differentiated profile and advancing its development for patients in need.”
Camilla Chong, Chief Medical Officer of InflaRx, commented: “Results from our phase 2a study indicate INF904’s positive safety profile to date and show promising signals of clinical benefit in both hidradenitis suppurativa and chronic spontaneous urticaria.”